Biotek-snakken — Februar 2025
-
Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study
https://storage.mfn.se/f49ff507-a199-47f0-bcd9-c763cd153496/ascelia-pharma-q4-2024-en.pdf
-
"A presentation for analysts, investors and media will be held today 7 February 2025 at 10:00am CET."
Ikke "idag 15 augusti kl. 10:00." som der står
i den svenske udgave
-
Og som sagt, den burde ikke stige mere end op til kurs måske 10-15 hvis vi strækker os langt.. igen, jeg kan sagtens se den stige til 15, men så er det mest fordi, aftalen betyder de styrker deres kapital beredskab og således forbedre forhandlings styrken ifm nye aftaler på pipeline.
-
Medix to submit final version of tesofensine application following interaction with COFEPRIS
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its partner Medix sees a clear regulatory path forward for tesofensine following discussions with the Mexican regulatory agency COFEPRIS.
Since the message from COFEPRIS, communicated in Saniona’s press releases of November 6 and November 12, 2024, Productos Medix S.A. de S.V. (Medix) has worked closely with COFEPRI
-
Photocure med glemt link
https://bladdercancer.libsyn.com/shining-a-blue-light-on-bladder-cancer-photocures-impact
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind